CN107629109A - 从细胞中有效提取蛋白质的方法 - Google Patents
从细胞中有效提取蛋白质的方法 Download PDFInfo
- Publication number
- CN107629109A CN107629109A CN201710593190.6A CN201710593190A CN107629109A CN 107629109 A CN107629109 A CN 107629109A CN 201710593190 A CN201710593190 A CN 201710593190A CN 107629109 A CN107629109 A CN 107629109A
- Authority
- CN
- China
- Prior art keywords
- cell
- protein
- reagent
- hpv
- brij
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 237
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 229
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 227
- 238000000605 extraction Methods 0.000 title description 73
- 239000000284 extract Substances 0.000 claims abstract description 232
- -1 polyoxyethylene Polymers 0.000 claims abstract description 128
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 104
- 239000000203 mixture Substances 0.000 claims abstract description 69
- 150000005215 alkyl ethers Chemical class 0.000 claims abstract description 50
- 241000700605 Viruses Species 0.000 claims abstract description 39
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 215
- 238000006386 neutralization reaction Methods 0.000 claims description 115
- 238000001514 detection method Methods 0.000 claims description 62
- 239000003599 detergent Substances 0.000 abstract description 54
- 210000004027 cell Anatomy 0.000 description 268
- 235000018102 proteins Nutrition 0.000 description 193
- 239000000523 sample Substances 0.000 description 140
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 118
- 239000007853 buffer solution Substances 0.000 description 72
- 239000003795 chemical substances by application Substances 0.000 description 71
- 150000001413 amino acids Chemical group 0.000 description 44
- 235000001014 amino acid Nutrition 0.000 description 41
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 39
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 38
- 239000002245 particle Substances 0.000 description 34
- 102000000470 PDZ domains Human genes 0.000 description 32
- 108050008994 PDZ domains Proteins 0.000 description 32
- 239000000654 additive Substances 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000003398 denaturant Substances 0.000 description 26
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 239000000834 fixative Substances 0.000 description 23
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 22
- 229920001184 polypeptide Polymers 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- 239000011536 extraction buffer Substances 0.000 description 19
- 229940038384 octadecane Drugs 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- 230000000996 additive effect Effects 0.000 description 18
- 239000000872 buffer Substances 0.000 description 18
- 239000007983 Tris buffer Substances 0.000 description 16
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 16
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 16
- 239000010931 gold Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 230000000711 cancerogenic effect Effects 0.000 description 15
- 231100000315 carcinogenic Toxicity 0.000 description 15
- 229910052737 gold Inorganic materials 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 15
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000007689 inspection Methods 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 13
- 235000013601 eggs Nutrition 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 102220002645 rs104894309 Human genes 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000000751 protein extraction Methods 0.000 description 10
- 230000009870 specific binding Effects 0.000 description 10
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 238000002331 protein detection Methods 0.000 description 8
- 239000004793 Polystyrene Substances 0.000 description 7
- BQODPTQLXVVEJG-UHFFFAOYSA-N [O].C=C Chemical compound [O].C=C BQODPTQLXVVEJG-UHFFFAOYSA-N 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 229920002223 polystyrene Polymers 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 102100027240 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Human genes 0.000 description 6
- 101710137278 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 238000004043 dyeing Methods 0.000 description 6
- 239000003344 environmental pollutant Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000009826 neoplastic cell growth Effects 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 231100000719 pollutant Toxicity 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 241000700584 Simplexvirus Species 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 239000012459 cleaning agent Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000001215 fluorescent labelling Methods 0.000 description 5
- 231100000590 oncogenic Toxicity 0.000 description 5
- 230000002246 oncogenic effect Effects 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 4
- 229920002972 Acrylic fiber Polymers 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000009608 Papillomavirus Infections Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 210000003679 cervix uteri Anatomy 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 210000000969 egg white Anatomy 0.000 description 4
- 235000014103 egg white Nutrition 0.000 description 4
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000123 paper Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920002689 polyvinyl acetate Polymers 0.000 description 4
- 239000011118 polyvinyl acetate Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- 229920002955 Art silk Polymers 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 239000004425 Makrolon Substances 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical group OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 3
- 229920001363 Polidocanol Polymers 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 102100036221 Tax1-binding protein 3 Human genes 0.000 description 3
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical class [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- MEGHWIAOTJPCHQ-UHFFFAOYSA-N ethenyl butanoate Chemical compound CCCC(=O)OC=C MEGHWIAOTJPCHQ-UHFFFAOYSA-N 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000006174 pH buffer Substances 0.000 description 3
- 238000009595 pap smear Methods 0.000 description 3
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical class CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 3
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000193 polymethacrylate Polymers 0.000 description 3
- 229920000056 polyoxyethylene ether Polymers 0.000 description 3
- 229920006324 polyoxymethylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- 235000019263 trisodium citrate Nutrition 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- WFLOTYSKFUPZQB-UHFFFAOYSA-N 1,2-difluoroethene Chemical group FC=CF WFLOTYSKFUPZQB-UHFFFAOYSA-N 0.000 description 2
- AZLWQVJVINEILY-UHFFFAOYSA-N 2-(2-dodecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCOCCOCCO AZLWQVJVINEILY-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 206010008263 Cervical dysplasia Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000590691 Homo sapiens MAGUK p55 subfamily member 2 Proteins 0.000 description 2
- 101001078087 Homo sapiens Reticulocalbin-2 Proteins 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920002884 Laureth 4 Polymers 0.000 description 2
- 244000147568 Laurus nobilis Species 0.000 description 2
- 235000017858 Laurus nobilis Nutrition 0.000 description 2
- 102100032498 MAGUK p55 subfamily member 2 Human genes 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001115401 Marburgvirus Species 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 102100025337 Reticulocalbin-2 Human genes 0.000 description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 201000003761 Vaginal carcinoma Diseases 0.000 description 2
- 208000018777 Vulvar intraepithelial neoplasia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 201000004306 epidermodysplasia verruciformis Diseases 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 201000006958 oropharynx cancer Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 208000030940 penile carcinoma Diseases 0.000 description 2
- 201000008174 penis carcinoma Diseases 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
- 229960002226 polidocanol Drugs 0.000 description 2
- 229920001596 poly (chlorostyrenes) Polymers 0.000 description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 229940016590 sarkosyl Drugs 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 239000011163 secondary particle Substances 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- 208000013013 vulvar carcinoma Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- CSPVUHYZUZZRGF-RNFRBKRXSA-N (4R,6R)-hydroxy-2,2,6-trimethylcyclohexanone Chemical compound C[C@@H]1C[C@@H](O)CC(C)(C)C1=O CSPVUHYZUZZRGF-RNFRBKRXSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
- XNPKNHHFCKSMRV-UHFFFAOYSA-N 4-(cyclohexylamino)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCNC1CCCCC1 XNPKNHHFCKSMRV-UHFFFAOYSA-N 0.000 description 1
- 102100027123 55 kDa erythrocyte membrane protein Human genes 0.000 description 1
- 229930185327 Actinol Natural products 0.000 description 1
- 102100036775 Afadin Human genes 0.000 description 1
- 108010075409 Alanine carboxypeptidase Proteins 0.000 description 1
- 102100036514 Amyloid-beta A4 precursor protein-binding family A member 1 Human genes 0.000 description 1
- 102100036440 Amyloid-beta A4 precursor protein-binding family A member 3 Human genes 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102100032850 Beta-1-syntrophin Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000008001 CAPS buffer Substances 0.000 description 1
- YCSMVPSDJIOXGN-UHFFFAOYSA-N CCCCCCCCCCCC[Na] Chemical compound CCCCCCCCCCCC[Na] YCSMVPSDJIOXGN-UHFFFAOYSA-N 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100026679 Carboxypeptidase Q Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 108700019745 Disks Large Homolog 4 Proteins 0.000 description 1
- 102100024099 Disks large homolog 1 Human genes 0.000 description 1
- 102100022264 Disks large homolog 4 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 102100027623 FERM and PDZ domain-containing protein 4 Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 101150048348 GP41 gene Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101000928246 Homo sapiens Afadin Proteins 0.000 description 1
- 101000928690 Homo sapiens Amyloid-beta A4 precursor protein-binding family A member 1 Proteins 0.000 description 1
- 101000928673 Homo sapiens Amyloid-beta A4 precursor protein-binding family A member 3 Proteins 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868444 Homo sapiens Beta-1-syntrophin Proteins 0.000 description 1
- 101000910846 Homo sapiens Carboxypeptidase Q Proteins 0.000 description 1
- 101001053984 Homo sapiens Disks large homolog 1 Proteins 0.000 description 1
- 101001053980 Homo sapiens Disks large homolog 2 Proteins 0.000 description 1
- 101000951365 Homo sapiens Disks large-associated protein 5 Proteins 0.000 description 1
- 101000862373 Homo sapiens FERM and PDZ domain-containing protein 4 Proteins 0.000 description 1
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 1
- 101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 1
- 101001042360 Homo sapiens LIM domain kinase 2 Proteins 0.000 description 1
- 101001018294 Homo sapiens Microtubule-associated serine/threonine-protein kinase 3 Proteins 0.000 description 1
- 101001018298 Homo sapiens Microtubule-associated serine/threonine-protein kinase 4 Proteins 0.000 description 1
- 101000988394 Homo sapiens PDZ and LIM domain protein 5 Proteins 0.000 description 1
- 101001113469 Homo sapiens Partitioning defective 6 homolog alpha Proteins 0.000 description 1
- 101000922137 Homo sapiens Peripheral plasma membrane protein CASK Proteins 0.000 description 1
- 101000942742 Homo sapiens Protein lin-7 homolog A Proteins 0.000 description 1
- 101000609959 Homo sapiens Protein piccolo Proteins 0.000 description 1
- 101000867413 Homo sapiens Segment polarity protein dishevelled homolog DVL-1 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 101000807948 Human papillomavirus 45 Protein E6 Proteins 0.000 description 1
- 101000954519 Human papillomavirus type 18 Protein E6 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100029874 Kappa-casein Human genes 0.000 description 1
- 108050007394 Kinesin-like protein KIF20B Proteins 0.000 description 1
- 102100026023 LIM domain kinase 1 Human genes 0.000 description 1
- 102100021756 LIM domain kinase 2 Human genes 0.000 description 1
- 241000218194 Laurales Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 102100028328 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Human genes 0.000 description 1
- 101710137272 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Proteins 0.000 description 1
- 102100028327 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3 Human genes 0.000 description 1
- 101710137274 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100033251 Microtubule-associated serine/threonine-protein kinase 3 Human genes 0.000 description 1
- 102100033252 Microtubule-associated serine/threonine-protein kinase 4 Human genes 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 206010056286 Nipple neoplasm Diseases 0.000 description 1
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 102100023711 Partitioning defective 6 homolog alpha Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100032928 Protein lin-7 homolog A Human genes 0.000 description 1
- 102100039154 Protein piccolo Human genes 0.000 description 1
- 101710089165 Protein white Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 102100035772 Regulator of G-protein signaling 12 Human genes 0.000 description 1
- 101710148337 Regulator of G-protein signaling 12 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100032758 Segment polarity protein dishevelled homolog DVL-1 Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 102000002154 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Human genes 0.000 description 1
- 108010001288 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Proteins 0.000 description 1
- 101710193790 Tax1-binding protein 3 Proteins 0.000 description 1
- 241001627955 Tetraodon lineatus Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N anhydrous creatine Natural products NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 206010006060 bowenoid papulosis Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 101150069842 dlg4 gene Proteins 0.000 description 1
- MOVLUIIHXYDXBS-UHFFFAOYSA-N dodecan-1-ol;ethanol Chemical compound CCO.CCCCCCCCCCCCO MOVLUIIHXYDXBS-UHFFFAOYSA-N 0.000 description 1
- ZCGCUCKKRUAGMA-UHFFFAOYSA-N dodecane oxirane Chemical compound CCCCCCCCCCCC.C1CO1 ZCGCUCKKRUAGMA-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 125000001033 ether group Polymers 0.000 description 1
- 150000002170 ethers Polymers 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940100556 laureth-23 Drugs 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 229950006462 lauromacrogol 400 Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 208000020668 oropharyngeal carcinoma Diseases 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 230000002023 papillomaviral effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000007864 suspending Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 201000004916 vulva carcinoma Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4044—Concentrating samples by chemical techniques; Digestion; Chemical decomposition
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/985,547 | 2007-11-14 | ||
| US11/985,547 US9207240B2 (en) | 2007-11-14 | 2007-11-14 | Method of efficient extraction of protein from cells |
| CN200880124680.0A CN101910400B (zh) | 2007-11-14 | 2008-11-14 | 从细胞中有效提取蛋白质的方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880124680.0A Division CN101910400B (zh) | 2007-11-14 | 2008-11-14 | 从细胞中有效提取蛋白质的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107629109A true CN107629109A (zh) | 2018-01-26 |
Family
ID=40624059
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710593190.6A Pending CN107629109A (zh) | 2007-11-14 | 2008-11-14 | 从细胞中有效提取蛋白质的方法 |
| CN200880124680.0A Expired - Fee Related CN101910400B (zh) | 2007-11-14 | 2008-11-14 | 从细胞中有效提取蛋白质的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880124680.0A Expired - Fee Related CN101910400B (zh) | 2007-11-14 | 2008-11-14 | 从细胞中有效提取蛋白质的方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9207240B2 (https=) |
| EP (1) | EP2222838B1 (https=) |
| JP (1) | JP5787519B2 (https=) |
| CN (2) | CN107629109A (https=) |
| AU (1) | AU2008322473B2 (https=) |
| BR (1) | BRPI0820177B8 (https=) |
| CA (1) | CA2705765C (https=) |
| ES (1) | ES2456341T3 (https=) |
| WO (1) | WO2009065091A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8962262B2 (en) * | 2006-05-11 | 2015-02-24 | Arbor Vita Corporation | Method of protein extraction from cells |
| US20100003704A1 (en) * | 2008-06-13 | 2010-01-07 | Shuling Cheng | IN SITU detection of early stages and late stages HPV infection |
| US9207240B2 (en) | 2007-11-14 | 2015-12-08 | Arbor Vita Corporation | Method of efficient extraction of protein from cells |
| BR112012004699B1 (pt) | 2009-09-03 | 2019-10-15 | Becton, Dickinson And Company | Métodos, composições e kits para lise química direta |
| US8282895B2 (en) * | 2009-09-15 | 2012-10-09 | Qiagen Gaithersburg, Inc. | Reagent cabinet system |
| US8994937B2 (en) | 2012-04-18 | 2015-03-31 | Hewlett-Packard Development Company, L.P. | Surface enhanced Raman spectroscopy calibration curve generating systems |
| US9680916B2 (en) | 2013-08-01 | 2017-06-13 | Flowtraq, Inc. | Methods and systems for distribution and retrieval of network traffic records |
| JP6397224B2 (ja) * | 2014-06-04 | 2018-09-26 | 田中貴金属工業株式会社 | 免疫学的測定試薬におけるプロゾーン現象の解消法 |
| CN104237198A (zh) * | 2014-07-31 | 2014-12-24 | 中国人民解放军第二军医大学 | 一种判定中药材或中药饮片是否染色的方法 |
| EP3465217B1 (en) * | 2016-05-31 | 2025-09-03 | Roche Diagnostics GmbH | Method for serological detection of viral antigens |
| CN107621462B (zh) * | 2016-07-13 | 2020-03-31 | 王志伟 | 一种组织透明化液sut及其制备和应用 |
| WO2018130072A1 (zh) * | 2017-01-12 | 2018-07-19 | 厦门大学 | 稳定呼吸道合胞病毒融合蛋白的方法 |
| BR112020012490A2 (pt) * | 2017-12-22 | 2020-11-24 | Basf Plant Science Company Gmbh | método para a extração de proteínas ligadas à membrana e composição |
| JP7267548B2 (ja) * | 2019-04-24 | 2023-05-02 | 株式会社ニップン | トマト黄化葉巻ウイルス（ｔｙｌｃｖ）の免疫学的診断法 |
| CN112213164A (zh) * | 2019-07-12 | 2021-01-12 | 温州医科大学附属第一医院 | 一种总蛋白提取试剂盒及提取方法 |
| CN116223793A (zh) * | 2023-02-14 | 2023-06-06 | 上海乐备实生物技术有限公司 | 一种用于外泌体中补体检测的裂解液及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0363110A2 (en) * | 1988-10-07 | 1990-04-11 | Johnson & Johnson Clinical Diagnostics, Inc. | High pH extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen |
| CN1413195A (zh) * | 1999-12-08 | 2003-04-23 | 辛根塔参与股份公司 | 用于新烟碱基杀虫剂的免疫测定法 |
| US20040101947A1 (en) * | 2002-11-01 | 2004-05-27 | Promega Corporation | Cell lysis composition, methods of use, apparatus and kit |
| CN1984989A (zh) * | 2004-06-09 | 2007-06-20 | 病原体切除与诊断科技公司 | 用于从样品中除去靶分析物的包埋在多孔底物中的颗粒 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3546334A (en) * | 1965-05-21 | 1970-12-08 | Lerner Lab Inc | Composition for fixing and protecting a smear of body cells and method of applying same |
| US3303038A (en) * | 1965-07-29 | 1967-02-07 | Ethicon Inc | Process of forming collagen articles and dispersions |
| JPS5535088B2 (https=) * | 1971-09-10 | 1980-09-11 | ||
| US4578282A (en) * | 1982-02-04 | 1986-03-25 | Harrison James S | Composition for diagnostic reagents |
| US4766065A (en) | 1984-08-23 | 1988-08-23 | Becton Dickinson And Company | Detection of cell membrane protein |
| US4649192A (en) * | 1985-05-30 | 1987-03-10 | Smith Kline-Rit | Method for the isolation and purification of hepatitis B surface antigen using polysorbate |
| US4857300A (en) * | 1987-07-27 | 1989-08-15 | Cytocorp, Inc. | Cytological and histological fixative formulation and methods for using same |
| US5047325A (en) | 1988-10-07 | 1991-09-10 | Eastman Kodak Company | Wash solution containing a cationic surfactant and its use in chlamydial and gonococcal determinations |
| US5081010A (en) | 1989-02-09 | 1992-01-14 | Eastman Kodak Company | Extraction composition, test kit and their use to extract or determine herpes simplex viral antigen |
| US5104640A (en) * | 1989-03-17 | 1992-04-14 | Wescor, Inc. | Fixative composition for fixing blood smears to slides |
| US5256571A (en) * | 1991-05-01 | 1993-10-26 | Cytyc Corporation | Cell preservative solution |
| US5196182A (en) * | 1991-05-08 | 1993-03-23 | Streck Laboratories, Inc. | Tissue fixative |
| US5773277A (en) * | 1992-06-26 | 1998-06-30 | Seikagaku Kogyo Kabushiki Kaisha | Crystalline chondroitinase isolated from Proteus vulgaris ATCC 6896 |
| US5432056A (en) * | 1993-11-15 | 1995-07-11 | Ventana Medical Systems, Inc. | Bisulfite-based tissue fixative |
| US5658749A (en) * | 1994-04-05 | 1997-08-19 | Corning Clinical Laboratories, Inc. | Method for processing mycobacteria |
| US5620869A (en) * | 1995-09-28 | 1997-04-15 | Becton, Dickinson And Company | Methods for reducing inhibition of nucleic acid amplification reactions |
| US7306926B2 (en) * | 1998-07-01 | 2007-12-11 | Mtm Laboratories Ag | Method for detecting carcinomas in a solubilized cervical body sample |
| US6245568B1 (en) | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
| US20050019841A1 (en) * | 1999-05-14 | 2005-01-27 | Arbor Vita Corporation | Modulation of signaling pathways |
| US20060148711A1 (en) * | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US20050037969A1 (en) * | 1999-05-14 | 2005-02-17 | Arbor Vita Corporation | Molecular interactions in hematopoietic cells |
| US6488671B1 (en) * | 1999-10-22 | 2002-12-03 | Corazon Technologies, Inc. | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same |
| US6337189B1 (en) * | 2000-02-08 | 2002-01-08 | Streck Laboratories, Inc. | Fixative system, method and composition for biological testing |
| US6436662B1 (en) * | 2000-04-04 | 2002-08-20 | Digene Corporation | Device and method for cytology slide preparation |
| WO2002007751A1 (en) * | 2000-07-25 | 2002-01-31 | Axcell Biosciences Corporation | Identification and isolation of novel polypeptides having pdz domains and methods of using same |
| US20030175852A1 (en) * | 2000-09-15 | 2003-09-18 | Kalra Krishan L | Ehancement of in situ hybridization |
| US7312041B2 (en) * | 2001-02-16 | 2007-12-25 | Arbor Vita Corporation | Methods of diagnosing cervical cancer |
| DK1402015T3 (da) | 2001-06-22 | 2011-12-05 | Hoffmann La Roche | Opløseligt kompleks omfattende et retroviralt overfladeglycoprotein og FkpA eller SlyD |
| US20050032105A1 (en) * | 2001-10-12 | 2005-02-10 | Bair Robert Jackson | Compositions and methods for using a solid support to purify DNA |
| BR0314155A (pt) | 2002-09-09 | 2005-07-05 | Arbor Vita Corp | Métodos para diagnosticar câncer cervical |
| DE60300339T2 (de) | 2003-08-25 | 2006-04-13 | Mtm Laboratories Ag | Verfahren zum Nachweis von Karzinomen in solubilisierten zervikalen Körperproben |
| DE602004026912D1 (de) * | 2003-12-16 | 2010-06-10 | Qiagen North American Holdings | Formulierungen und verfahren zum denaturieren von proteinen |
| JP5030594B2 (ja) * | 2003-12-23 | 2012-09-19 | アルボー ビータ コーポレーション | Ｈｐｖの発癌性株に対する抗体およびそれらの使用方法 |
| US7723044B2 (en) * | 2004-04-15 | 2010-05-25 | Allied Biotech, Inc. | Methods and apparatus for detection of viral infection |
| US8962262B2 (en) * | 2006-05-11 | 2015-02-24 | Arbor Vita Corporation | Method of protein extraction from cells |
| US9207240B2 (en) | 2007-11-14 | 2015-12-08 | Arbor Vita Corporation | Method of efficient extraction of protein from cells |
-
2007
- 2007-11-14 US US11/985,547 patent/US9207240B2/en active Active
-
2008
- 2008-11-14 AU AU2008322473A patent/AU2008322473B2/en not_active Ceased
- 2008-11-14 CN CN201710593190.6A patent/CN107629109A/zh active Pending
- 2008-11-14 CA CA2705765A patent/CA2705765C/en not_active Expired - Fee Related
- 2008-11-14 CN CN200880124680.0A patent/CN101910400B/zh not_active Expired - Fee Related
- 2008-11-14 BR BRPI0820177A patent/BRPI0820177B8/pt not_active IP Right Cessation
- 2008-11-14 ES ES08850323.0T patent/ES2456341T3/es active Active
- 2008-11-14 JP JP2010534253A patent/JP5787519B2/ja not_active Expired - Fee Related
- 2008-11-14 WO PCT/US2008/083707 patent/WO2009065091A1/en not_active Ceased
- 2008-11-14 EP EP08850323.0A patent/EP2222838B1/en not_active Not-in-force
-
2015
- 2015-11-04 US US14/932,693 patent/US9995745B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0363110A2 (en) * | 1988-10-07 | 1990-04-11 | Johnson & Johnson Clinical Diagnostics, Inc. | High pH extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen |
| CN1413195A (zh) * | 1999-12-08 | 2003-04-23 | 辛根塔参与股份公司 | 用于新烟碱基杀虫剂的免疫测定法 |
| US20040101947A1 (en) * | 2002-11-01 | 2004-05-27 | Promega Corporation | Cell lysis composition, methods of use, apparatus and kit |
| CN1984989A (zh) * | 2004-06-09 | 2007-06-20 | 病原体切除与诊断科技公司 | 用于从样品中除去靶分析物的包埋在多孔底物中的颗粒 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2222838A4 (en) | 2011-01-05 |
| ES2456341T3 (es) | 2014-04-22 |
| US9207240B2 (en) | 2015-12-08 |
| BRPI0820177A2 (pt) | 2014-11-04 |
| US9995745B2 (en) | 2018-06-12 |
| US20160216258A1 (en) | 2016-07-28 |
| JP5787519B2 (ja) | 2015-09-30 |
| JP2011503208A (ja) | 2011-01-27 |
| CN101910400B (zh) | 2017-06-27 |
| CA2705765A1 (en) | 2009-05-22 |
| AU2008322473A1 (en) | 2009-05-22 |
| BRPI0820177B8 (pt) | 2021-07-27 |
| US20090123910A1 (en) | 2009-05-14 |
| AU2008322473B2 (en) | 2014-07-03 |
| WO2009065091A1 (en) | 2009-05-22 |
| EP2222838A1 (en) | 2010-09-01 |
| CA2705765C (en) | 2018-12-11 |
| EP2222838B1 (en) | 2014-01-22 |
| BRPI0820177B1 (pt) | 2019-07-02 |
| CN101910400A (zh) | 2010-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107629109A (zh) | 从细胞中有效提取蛋白质的方法 | |
| US8962262B2 (en) | Method of protein extraction from cells | |
| Drew | Diagnosis of cytomegalovirus infection | |
| CN109254155B (zh) | 一种检测非洲猪瘟病毒抗原胶体金免疫层析试纸及制备方法和应用 | |
| Heino et al. | Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma | |
| Aaltonen et al. | Poor antibody response against human papillomavirus in adult-onset laryngeal papillomatosis | |
| Zhang et al. | Dengue virus growth, purification, and fluorescent labeling | |
| CN105158471A (zh) | 人细小病毒B19型IgM抗体检测试剂盒及其制备方法 | |
| Drew | Diagnostic virology | |
| Iwa et al. | Cytodiagnosis of parvoviruS b19 infection from ascites fluid of hydrops fetalis: Report of a case | |
| Paul | Developing Low-Cost Paper-Based Assays to Reduce Overtreatment at the Point of Care | |
| KHAIRULLAH | Comparison of two monoclonal antibody kits with cell culture isolation in the detection of respiratory virus antigens | |
| CN115594759A (zh) | 犬轮状病毒单克隆抗体对及其应用 | |
| BRPI0805220A2 (pt) | métodos para produzir um extrato de proteìna a partir de células fixas e para detectar uma proteìna, sistema e kit para produzir um extrato de proteìna, e, método para extrair uma proteìna viral alvo de uma amostra de célula | |
| Asante | Hepatitis E-Virus (HEV): comparative evaluation of IgG antibody assays in a low-endemicity setting | |
| TW200427837A (en) | Monoclonal antibody of porcine endogenous retrovirus (PERV) capsid, hybridoma generating the antibody, and use thereof | |
| Yu-kai et al. | JKK Li, T. Johnson, YY Yang and V. Shore (USA) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180126 |
|
| WD01 | Invention patent application deemed withdrawn after publication |